ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式（ヒル表記法）:
C22H43N5O13
CAS番号:
分子量:
585.60
MDL number:
UNSPSC Code:
41116107
EC Number:
253-538-5
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
amikacin
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
N([C@H]1[C@@H]([C@H]([C@@H]([C@H](C1)N)O[C@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CN)O)O[C@H]2O[C@@H]([C@H]([C@@H]([C@H]2O)N)O)CO)C(=O)[C@@H](O)CCN
InChI
1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1
InChI key
LKCWBDHBTVXHDL-RMDFUYIESA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Amikacin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Sophia B Georghiou et al.
PloS one, 7(3), e33275-e33275 (2012-04-06)
Rapid molecular diagnostics for detecting multidrug-resistant and extensively drug-resistant tuberculosis (M/XDR-TB) primarily identify mutations in Mycobacterium tuberculosis (Mtb) genes associated with drug resistance. Their accuracy, however, is dependent largely on the strength of the association between a specific mutation and
Amikacin.
R D Meyer
Annals of internal medicine, 95(3), 328-332 (1981-09-01)
P Van der Auwera
The Journal of antimicrobial chemotherapy, 27 Suppl C, 63-71 (1991-05-01)
The pharmacokinetic parameters of amikacin given once daily were compared to those of amikacin given bd at different daily dosages. In adult patients, 'peak' serum concentrations (30 min after 30 min infusion) were linearly proportional to the dose given with